JERUSALEM, August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 19th Annual Global Investment Conference, taking place [...]
JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very pleased to welcome [...]
JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: [...]
JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed [...]
JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel [...]
JERUSALEM, June 27, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and [...]
JERUSALEM, June 6, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented [...]
JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel. Oppenheimer's 17th [...]
JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of [...]
JERUSALEM, May 2, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company is developing a new drug candidate, a weight loss treatment [...]